Answers are grounded in this paper and cite their sources.
Anticoagulation remains the unchallenged treatment of choice for patients with nonvalvular atrial fibrillation at moderate to high risk of thromboembolic complications.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Patrono et al. (2013) conducted a review in Atrial Fibrillation and Atherothrombotic Vascular Disease. Antithrombotic Therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: